EE03902B1 - Osakesed, nende valmistamismeetod ja kasutamine, farmatseutiline doseerimisvorm ja selle valmistamismeetod, tahke dispersioon ning farmatseutiline pakend - Google Patents

Osakesed, nende valmistamismeetod ja kasutamine, farmatseutiline doseerimisvorm ja selle valmistamismeetod, tahke dispersioon ning farmatseutiline pakend

Info

Publication number
EE03902B1
EE03902B1 EE9800304A EE9800304A EE03902B1 EE 03902 B1 EE03902 B1 EE 03902B1 EE 9800304 A EE9800304 A EE 9800304A EE 9800304 A EE9800304 A EE 9800304A EE 03902 B1 EE03902 B1 EE 03902B1
Authority
EE
Estonia
Prior art keywords
preparation
pharmaceutical
particles
dosage form
solid dispersion
Prior art date
Application number
EE9800304A
Other languages
English (en)
Estonian (et)
Other versions
EE9800304A (et
Inventor
Elvire Colette Baert Lieven
Verreck Geert
Thon Dany
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26142825&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE03902(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of EE9800304A publication Critical patent/EE9800304A/xx
Publication of EE03902B1 publication Critical patent/EE03902B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EE9800304A 1996-05-20 1997-05-12 Osakesed, nende valmistamismeetod ja kasutamine, farmatseutiline doseerimisvorm ja selle valmistamismeetod, tahke dispersioon ning farmatseutiline pakend EE03902B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP96201430 1996-05-20
EP97200698 1997-03-07
PCT/EP1997/002507 WO1997044014A1 (fr) 1996-05-20 1997-05-12 Compositions antifongiques avec biodisponibilite amelioree

Publications (2)

Publication Number Publication Date
EE9800304A EE9800304A (et) 1999-02-15
EE03902B1 true EE03902B1 (et) 2002-12-16

Family

ID=26142825

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9800304A EE03902B1 (et) 1996-05-20 1997-05-12 Osakesed, nende valmistamismeetod ja kasutamine, farmatseutiline doseerimisvorm ja selle valmistamismeetod, tahke dispersioon ning farmatseutiline pakend

Country Status (33)

Country Link
US (4) US6509038B2 (fr)
EP (1) EP0904060B1 (fr)
JP (1) JP3391801B2 (fr)
KR (1) KR19990044257A (fr)
CN (1) CN1165291C (fr)
AR (1) AR007195A1 (fr)
AT (1) ATE255883T1 (fr)
AU (1) AU722101B2 (fr)
BG (1) BG64368B1 (fr)
BR (1) BR9706897B1 (fr)
CA (1) CA2240161C (fr)
CY (1) CY2434B1 (fr)
CZ (1) CZ293841B6 (fr)
DE (1) DE69726729T2 (fr)
DK (1) DK0904060T3 (fr)
EA (1) EA001219B1 (fr)
EE (1) EE03902B1 (fr)
ES (1) ES2212810T3 (fr)
HR (1) HRP970270B1 (fr)
HU (1) HU227745B1 (fr)
ID (1) ID16926A (fr)
IL (1) IL124935A (fr)
MX (1) MX9805418A (fr)
MY (1) MY123827A (fr)
NO (1) NO320495B1 (fr)
NZ (1) NZ330739A (fr)
PL (1) PL188566B1 (fr)
PT (1) PT904060E (fr)
SI (1) SI0904060T1 (fr)
SK (1) SK284145B6 (fr)
TR (1) TR199801225T2 (fr)
TW (1) TW460282B (fr)
WO (1) WO1997044014A1 (fr)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990001564A (ko) * 1997-06-16 1999-01-15 유충식 용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제
PT1039909E (pt) * 1997-12-31 2003-02-28 Choongwae Pharma Corp Metodo de producao e composicao de uma preparacao oral de itraconazole
KR100288890B1 (ko) * 1997-12-31 2001-05-02 최현식 이트라코나졸 경구용 제제 및 그의 제조방법
KR100514330B1 (ko) * 1997-12-31 2006-02-17 주식회사 중외제약 난용성 약물을 함유하는 코팅정
HU230295B1 (hu) 1998-01-07 2015-12-28 Meiji Seika Pharma Co., Ltd. Kristálytanilag stabil, amorf, cephalosporin tartalmú készítmény és eljárás előállítására
ES2157731B1 (es) * 1998-07-21 2002-05-01 Liconsa Liberacion Controlada Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion.
ES2251985T3 (es) * 1999-03-24 2006-05-16 R.P. Scherer Technologies, Inc. Particula granulada para mejorar la solubilidad acuosa de farmacos, y su procedimiento de preparacion.
KR100331529B1 (ko) * 1999-06-16 2002-04-06 민경윤 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법
EP1175205B1 (fr) 1999-11-12 2006-06-14 Abbott Laboratories Dispersion solide comrpenant ritonavir, fenofibrate ou griseofulvin
EP1239831B1 (fr) 1999-12-23 2012-10-31 Mayne Pharma International Pty Ltd. Compositions pharmaceutiques ameliorees pour medicaments peu solubles
FR2803748A1 (fr) * 2000-01-14 2001-07-20 Ethypharm Lab Prod Ethiques Composition d'itraconazole et procede de preparation
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
NZ522953A (en) * 2000-06-22 2005-10-28 Novartis Ag Tablet containing valsartan, microcrystalline cellulose, crospovidone, colloidal anhydrous silica/colloidal silicon dioxide and magnesium stearate
DE10038571A1 (de) * 2000-08-03 2002-02-14 Knoll Ag Zusammensetzungen und Dosierungsformen zur Anwendung in der Mundhöhle bei der Bhandlung von Mykosen
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US7037528B2 (en) 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US7659404B2 (en) 2001-02-14 2010-02-09 Tibotec Pharmaceuticals Ltd. Broad spectrum 2-(substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors
OA12464A (en) 2001-04-09 2006-05-24 Tibotec Pharm Ltd Broadspectrum 2-(substituted-amino)-benzoxazole sulfonamide HIV protease inhibitors.
WO2002092595A1 (fr) 2001-05-11 2002-11-21 Tibotec Pharmaceuticals Ltd. Inhibiteurs des proteases du vih a large spectre sous forme de 2-amino-benzoxazole sulfonamides
WO2002100407A1 (fr) * 2001-06-12 2002-12-19 Smartrix Technologies Inc. Granules d'itraconazole: formulations pharmaceutiques pour administration orale et procede de preparation de ces dernieres
JP2004534812A (ja) 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク 薬物および中性ポリマーの分散物の医薬組成物
KR100455216B1 (ko) * 2001-06-27 2004-11-09 한미약품 주식회사 난용성 항진균제의 경구투여용 조성물 및 이의 제조 방법
US7163700B2 (en) * 2001-07-31 2007-01-16 Capricorn Pharma, Inc. Amorphous drug beads
KR100438485B1 (ko) * 2001-08-13 2004-07-09 한국디디에스제약 주식회사 아졸류 항진균제의 약제학적 조성물
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
BR0212833A (pt) 2001-09-26 2004-10-13 Baxter Int Preparação de nanopartìculas de tamanho submìcron através de dispersão e de remoção de solvente ou de fase lìquida
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
UA79248C2 (en) 2001-11-09 2007-06-11 Janssen Pharmaceutica Nv Mandelate salts of substituted tetracyclic tetrahydrofuran derivatives
CA2363376A1 (fr) * 2001-11-16 2003-05-16 Bernard Charles Sherman Compositions pharmaceutiques solides, comprenant de l'itraconazole, destinees a l'administration orale
US6455557B1 (en) 2001-11-28 2002-09-24 Elan Pharmaceuticals, Inc. Method of reducing somnolence in patients treated with tizanidine
US20040220240A1 (en) * 2001-11-28 2004-11-04 Pellegrini Cara A. Method of increasing the extent of absorption of tizanidine
MY138657A (en) 2001-12-21 2009-07-31 Tibotec Pharm Ltd broadspectrum heterocyclic substituted phenyl containing sulfonamide hiv protease inhibitors
HRP20020124A2 (en) * 2002-02-11 2003-10-31 Pliva D D Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
EP1479666A4 (fr) 2002-02-28 2010-10-13 Japan Tobacco Inc Compose d'esters et ses utilisation en medecine
MY142238A (en) 2002-03-12 2010-11-15 Tibotec Pharm Ltd Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
IL165043A0 (en) 2002-05-17 2005-12-18 Tibotec Pharm Ltd broadspectrum substituted benzisoxazole sulfonamide hiv protease inhibitors
WO2004004683A1 (fr) * 2002-07-04 2004-01-15 Janssen Pharmaceutica N.V. Dispersions solides comprenant deux matrices polymeriques distinctes
NZ538714A (en) 2002-08-14 2007-03-30 Tibotec Pharm Ltd Broadspectrum substituted oxindole sulfonamide HIV protease inhibitors
US7815934B2 (en) * 2002-09-20 2010-10-19 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
US20040086567A1 (en) * 2002-10-30 2004-05-06 Pawan Seth Bioequivalent composition of itraconazole and a hydrophilic polymer
SI1438961T2 (sl) * 2003-01-14 2014-12-31 Cimex Pharma Ag Bioekvivalenten sestavek itrakonazola, dispergiranega v hidrofilnem polimeru
CN100594023C (zh) * 2003-02-03 2010-03-17 诺瓦提斯公司 药物制剂
ES2667668T3 (es) * 2003-07-17 2018-05-14 Janssen Sciences Ireland Uc Procedimiento para preparar partículas que contienen un antiviral
FR2857591B1 (fr) * 2003-07-17 2007-11-02 Ethypharm Sa Particules comprenant un principe actif sous forme de co-precipite
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
JP4832897B2 (ja) 2003-08-29 2011-12-07 日本たばこ産業株式会社 エステル誘導体及びその医薬用途
US20050058670A1 (en) * 2003-09-09 2005-03-17 Jong-Soo Woo Oral itraconazole composition which is not affected by ingested food and process for preparing same
ATE532509T1 (de) 2003-09-11 2011-11-15 Tibotec Pharm Ltd Mittel zur hemmung des eintritts des hiv-virus
US20050118265A1 (en) * 2003-11-28 2005-06-02 Anandi Krishnan Antifungal oral dosage forms and the methods for preparation
TWI350762B (en) * 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
GB0403098D0 (en) * 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
US20050249799A1 (en) * 2004-03-03 2005-11-10 Spherics, Inc. Polymeric drug delivery system for hydrophobic drugs
AR048650A1 (es) 2004-05-04 2006-05-10 Tibotec Pharm Ltd Derivados de (1,10b-dihidro-2-(aminocarbonil-fenil)-5h-pirazolo[1,5 c][1,3]benzoxazin-5-il)fenil metanona como inhibidores de la replicacion viral del vih
US7378441B2 (en) 2004-05-07 2008-05-27 Sequoia Pharmaceuticals, Inc. Resistance-repellent retroviral protease inhibitors
US7622581B2 (en) 2004-05-17 2009-11-24 Tibotec Pharmaceuticals Ltd. 6,7,8,9-substituted 1-phenyl-1,5-dihydro-pyrido[3,2-b]indol-2-ones useful as anti-infective pharmaceutical agents
CA2564027A1 (fr) 2004-05-17 2005-11-24 Tibotec Pharmaceuticals Ltd. 1-heterocyclyl-1,5-dihydro-pyrido[3,2-b]indol-2-ones
WO2005111044A1 (fr) 2004-05-17 2005-11-24 Tibotec Pharmaceuticals Ltd. 1,5-dihydropyrido[3,2-b]indol-2-ones substituees en position 4
WO2005117834A1 (fr) * 2004-05-27 2005-12-15 Janssen Pharmaceutica N.V. Dispersions solides d'un compose medicamenteux basique et d'un polymere renfermant des groupes acides
KR20050119397A (ko) * 2004-06-16 2005-12-21 보람제약주식회사 고상용해를 이용한 난용성 약물의 가용화 방법과 이를이용한 가용화 조성물
US20060030623A1 (en) * 2004-07-16 2006-02-09 Noboru Furukawa Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis
KR100708974B1 (ko) * 2004-07-19 2007-04-18 주식회사종근당 수용성 수지를 이용한 이트라코나졸 고체분산체
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
WO2006026504A2 (fr) * 2004-08-27 2006-03-09 Spherics, Inc. Formulations orales mucoadhesives de medicaments a permeabilite et solubilite elevees
US8101774B2 (en) * 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
KR20070072888A (ko) * 2004-10-25 2007-07-06 니뽄 다바코 산교 가부시키가이샤 용해성 및 안정성이 개선된 고형 제제 및 그의 제조 방법
CA2598204C (fr) 2004-11-09 2015-01-13 Board Of Regents, The University Of Texas System Composition de petites particules medicamenteuses chauffee et stabilisee
CA2605214C (fr) 2004-12-31 2016-07-12 Reddy Us Therapeutics, Inc. Nouveaux derives de benzylamine en tant qu'inhibiteurs de cetp
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
TW200710091A (en) 2005-04-11 2007-03-16 Tibotec Pharm Ltd (1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
JP5538718B2 (ja) * 2005-08-08 2014-07-02 アボット ゲーエムベーハー ウント コンパニー カーゲー 改善された生物学的利用能をもつイトラコナゾール組成物
WO2007017249A1 (fr) 2005-08-08 2007-02-15 Abbott Gmbh & Co. Kg Formes posologiques à biodisponibilité accrue
CA2619889C (fr) * 2005-08-22 2020-05-05 The Johns Hopkins University Utilisation d'itraconazole et de sels de celui-ci pour traiter le cancer
EP1991241A4 (fr) * 2006-02-23 2009-07-08 Iomedix Sleep Internat Srl Compositions et méthodes pour l'induction et la conservation d'un sommeil de qualité
US7994187B2 (en) 2006-04-03 2011-08-09 Tibotec Pharmaceuticals Ltd. HIV inhibiting 3,4-dihydro-imidazo[4,5-B]pyridin-5-ones
GB0607105D0 (en) * 2006-04-10 2006-05-17 Leuven K U Res & Dev Enhancing solubility and dissolution rate of poorly soluble drugs
SI2719378T1 (sl) 2006-06-19 2016-11-30 Alpharma Pharmaceuticals Llc Farmacevtski sestavki
KR20090027734A (ko) * 2006-07-27 2009-03-17 (주)아모레퍼시픽 난용성 약물의 나노입자를 포함하는 분말의 제조방법
WO2008063301A2 (fr) * 2006-10-11 2008-05-29 Alpharma, Inc. Compositions pharmaceutiques
JP2010526848A (ja) * 2007-05-11 2010-08-05 エフ．ホフマン−ラ ロシュ アーゲー 難溶性薬物用の医薬組成物
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
JP6073043B2 (ja) * 2007-08-21 2017-02-01 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 医薬品適用のための熱−動力学的混合
ES2560899T3 (es) 2007-09-14 2016-02-23 Wockhardt Limited Composiciones de diacereína
ES2392781T3 (es) 2007-09-27 2012-12-13 Wockhardt Limited Composiciones farmacéuticas de reína o diacereína
US20090130160A1 (en) * 2007-11-21 2009-05-21 Fiber Innovation Technology, Inc. Fiber for wound dressing
US8569364B2 (en) 2007-11-28 2013-10-29 Sequoia Pharmaceuticals, Inc. 5-substituted benzofurans as inhibitors of cytochrome P450 2D6
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20090196890A1 (en) * 2007-12-17 2009-08-06 Alpharma Pharmaceuticals, Llc Pharmaceutical compositions
WO2009087410A2 (fr) * 2008-01-11 2009-07-16 Cipla Limited Forme posologique pharmaceutique solide
US8906647B2 (en) 2008-02-21 2014-12-09 Sequoia Pharmaceuticals, Inc. Diamide inhibitors of cytochrome P450
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
WO2009114648A1 (fr) 2008-03-11 2009-09-17 Depomed Inc. Formes médicamenteuses à libération étendue de rétention gastrique comprenant des combinaisons d'un analgésique non opioïde et d'un analgésique opioïde
CN102065842A (zh) * 2008-04-15 2011-05-18 先灵公司 优选含有泊沙康唑和hpmcas的固体分散体形式的口服药物组合物
EA013132B1 (ru) * 2008-12-31 2010-02-26 Открытое Акционерное Общество "Верофарм" Противогрибковое средство для вагинального применения
CN101780046B (zh) * 2009-01-16 2011-09-21 北京化工大学 一种伊曲康唑复合粉体及其制备方法
JP5714600B2 (ja) 2009-12-18 2015-05-07 フリースランドカンピナ・ネーデルランド・ホールディング・ビー．ブイ．ＦｒｉｅｓｌａｎｄＣａｍｐｉｎａ Ｎｅｄｅｒｌａｎｄ Ｈｏｌｄｉｎｇ Ｂ．Ｖ． 共加工された錠用賦形剤混合物、その調製及び使用
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
JP2014503470A (ja) * 2010-10-14 2014-02-13 アボット ゲーエムベーハー ウント カンパニー カーゲー クルクミノイド固体分散製剤
CN102068416A (zh) * 2010-12-30 2011-05-25 安徽先求药业有限公司 一种含有伊曲康唑的口服固体制剂及其制备方法
CA2824639A1 (fr) 2011-02-17 2012-08-23 Ashish Chatterji Procede de cristallisation commandee d'un ingredient pharmaceutique actif a partir d'un etat liquide en surfusion par extrusion a chaud
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
JP2014521745A (ja) * 2011-08-16 2014-08-28 メルク・シャープ・アンド・ドーム・コーポレーション 安定した非晶質分散体を調製するための無機マトリックスと有機ポリマーの組み合わせの使用
EP2744803A2 (fr) 2011-08-18 2014-06-25 Dr. Reddy's Laboratories Ltd. Composés amines hétérocycliques substitués comme inhibiteurs de la protéine de transfert d'ester cholesterylique (cetp)
WO2013037396A1 (fr) * 2011-09-12 2013-03-21 Bioneer A/S Solution de polymère dans un principe actif pour forme posologique solide
MX352074B (es) 2011-09-27 2017-11-08 Dr Reddys Laboratories Ltd Derivados de 5-bencilaminometil-6-aminopirazolo [3,4-b] piridina como inhibidores de proteina de transferencia de ester de colesterilo (cetp) utiles para el tratamiento de aterosclerosis.
US20140128431A1 (en) 2012-04-03 2014-05-08 Hoffmann-Laroche Inc. Pharmaceutical composition with improved bioavailability, safety and tolerability
EP2649989B1 (fr) 2012-04-13 2017-10-18 King Saud University Procédé de préparation d'une dispersion solide, dispersion solide ainsi obtenue et son utilisation
KR20200065093A (ko) 2012-06-21 2020-06-08 메인 파마 인터내셔널 프로프라이어터리 리미티드 이트라코나졸 조성물 및 투여형, 그리고 이것들의 사용 방법
US9962446B2 (en) 2012-07-17 2018-05-08 Dow Global Technologies Llc Solid dispersion comprising a highly substituted hydroxyalkyl methylcellulose
WO2014076568A2 (fr) 2012-11-19 2014-05-22 Dr. Reddy's Laboratories Ltd. Compositions pharmaceutiques d'inhibiteurs de cetp
WO2014114575A1 (fr) 2013-01-22 2014-07-31 F. Hoffmann-La Roche Ag Composition pharmaceutique à biodisponibilité ameliorée
CN104721827A (zh) * 2013-12-18 2015-06-24 博瑞生物医药技术(苏州)有限公司 一种难溶性抗真菌药物固体分散体及其制备方法
US10259921B2 (en) * 2014-01-16 2019-04-16 Dow Global Technologies Llc Support materials for 3D printing
JP6810060B2 (ja) * 2015-06-09 2021-01-06 ダウ グローバル テクノロジーズ エルエルシー ３ｄ印刷用支持材料
CN109069460A (zh) * 2016-05-09 2018-12-21 分散技术有限责任公司 改进的药物制剂
WO2019043427A1 (fr) 2017-09-01 2019-03-07 Jordan Sweden Medical And Sterilization Company Formes posologiques à auto-dispersion rapide de déférasirox
ES2941364T3 (es) 2018-06-11 2023-05-22 Procter & Gamble Dispositivo fotoactivador para lavadora
CN109172532A (zh) * 2018-10-24 2019-01-11 北京哈三联科技有限责任公司 一种伊曲康唑分散片及其制备方法和应用
KR20220054311A (ko) * 2019-08-28 2022-05-02 루브리졸 어드밴스드 머티어리얼스, 인코포레이티드 선형 폴리(아크릴산) 중합체를 사용한 약물-중합체 무정형 고체 분산체
KR102266145B1 (ko) * 2019-09-26 2021-06-17 대봉엘에스 주식회사 비정질 에피나코나졸 고체 분산체
JP2024530727A (ja) 2021-08-25 2024-08-23 ビーエーエスエフ ソシエタス・ヨーロピア 直接打錠補助組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4218458A (en) * 1978-06-23 1980-08-19 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-aryloxy-methyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
EP0012523B2 (fr) * 1978-11-20 1988-02-03 American Home Products Corporation Compositions thérapeutiques à biodisponibilité accrue et procédé pour leur préparation
JPS5879915A (ja) * 1981-11-09 1983-05-13 Nippon Soda Co Ltd 棒状薬剤の製造方法
US4916134A (en) * 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
JPH0667840B2 (ja) * 1988-11-30 1994-08-31 萬有製薬株式会社 Ｎｂ―８１８の易吸収性製剤
US5028433A (en) 1988-11-30 1991-07-02 Banyu Pharmaceutical Co., Ltd. Readily absorbable drug formulation of NB-818
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
WO1992018106A1 (fr) * 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Procede de production d'une dispersion solide
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
RU2127733C1 (ru) * 1992-03-18 1999-03-20 Жансен Фармасетика Н.В. Стереоизомеры итраконазола или саперконазола, способ их получения, их комплексы и фармацевтическая композиция на их основе
DE4226753A1 (de) * 1992-08-13 1994-02-17 Basf Ag Wirkstoffe enthaltende Zubereitungen in Form fester Teilchen
PH30929A (en) * 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
JP3413238B2 (ja) * 1993-03-31 2003-06-03 オリンパス光学工業株式会社 位相制御膜構造体
JPH07112928A (ja) * 1993-10-15 1995-05-02 Freunt Ind Co Ltd 難溶性薬物の溶解性改善方法およびそれにより得られた粒状薬剤
FR2722984B1 (fr) * 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
JP2948111B2 (ja) 1994-09-16 1999-09-13 塩野義製薬株式会社 経口投与用油性組成物

Also Published As

Publication number Publication date
CZ293841B6 (cs) 2004-08-18
EP0904060A1 (fr) 1999-03-31
EA001219B1 (ru) 2000-12-25
SK84898A3 (en) 1999-03-12
TW460282B (en) 2001-10-21
NO320495B1 (no) 2005-12-12
NO982599L (no) 1998-11-19
HUP9901620A2 (hu) 1999-10-28
CA2240161A1 (fr) 1997-11-27
JP3391801B2 (ja) 2003-03-31
ID16926A (id) 1997-11-20
US9642806B2 (en) 2017-05-09
EP0904060B1 (fr) 2003-12-10
MY123827A (en) 2006-06-30
IL124935A (en) 2001-06-14
DE69726729T2 (de) 2004-12-02
NO982599D0 (no) 1998-06-05
EE9800304A (et) 1999-02-15
CN1165291C (zh) 2004-09-08
CA2240161C (fr) 2005-05-24
ATE255883T1 (de) 2003-12-15
US8591948B2 (en) 2013-11-26
US20010007678A1 (en) 2001-07-12
KR19990044257A (ko) 1999-06-25
CZ188598A3 (cs) 1998-11-11
IL124935A0 (en) 1999-01-26
ES2212810T3 (es) 2004-08-01
CY2434B1 (en) 2004-11-12
WO1997044014A1 (fr) 1997-11-27
HUP9901620A3 (en) 2000-03-28
AR007195A1 (es) 1999-10-13
DE69726729D1 (de) 2004-01-22
PL188566B1 (pl) 2005-02-28
PT904060E (pt) 2004-04-30
JPH11509238A (ja) 1999-08-17
US20030082239A1 (en) 2003-05-01
BR9706897A (pt) 1999-08-31
US20140134244A1 (en) 2014-05-15
BR9706897B1 (pt) 2010-09-21
US20060263436A1 (en) 2006-11-23
HRP970270A2 (en) 1998-04-30
AU722101B2 (en) 2000-07-20
DK0904060T3 (da) 2004-04-13
CN1209740A (zh) 1999-03-03
HRP970270B1 (en) 2005-02-28
BG64368B1 (bg) 2004-12-30
HU227745B1 (en) 2012-02-28
BG102532A (en) 1999-02-26
TR199801225T2 (xx) 1998-11-23
NZ330739A (en) 1999-06-29
US7081255B2 (en) 2006-07-25
EA199800571A1 (ru) 1998-12-24
SI0904060T1 (en) 2004-04-30
SK284145B6 (sk) 2004-10-05
PL330931A1 (en) 1999-06-07
AU2956297A (en) 1997-12-09
US6509038B2 (en) 2003-01-21
HK1018002A1 (en) 1999-12-10
MX9805418A (es) 1998-10-31

Similar Documents

Publication Publication Date Title
EE03902B1 (et) Osakesed, nende valmistamismeetod ja kasutamine, farmatseutiline doseerimisvorm ja selle valmistamismeetod, tahke dispersioon ning farmatseutiline pakend
EE200100319A (et) Reguleeritud vabanemisega galantamiinipreparaat, meetod selle valmistamiseks, seda sisaldav doseerimisvorm ning farmatseutiline pakend
EE04991B1 (et) Osake, ravimvorm, nende valmistamismeetodid, osakeste kasutamine ning farmatseutiline pakend
EE9800383A (et) Meetod bioloogiliselt sobivate biodegradeeruvate mikroosakeste valmistamiseks, mikroosakesed ja nendest koosnev materjal, farmatseutiline kompositsioon ning mikroosakeste kasutamine
EE05086B1 (et) Primidiini derivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod, kombinatsioon ning saadus
EE9700061A (et) Farmatseutiline aerosoolpreparaat ja selle valmistamismeetod
EE9700328A (et) Tahke oraalne preparaat, mis sisaldab toimeainena olansapiini, selle valmistamismeetod ja kasutamine
EE04417B1 (et) Peroraalne farmatseutiline pulseeriva vabanemisega annusvorm, selle valmistamise meetod ja kasutamine
FI954143L (fi) Kiinteitä lipidihiukkasia, bioaktiivisten aineiden hiukkasia, menetelmiä niiden valmistamiseksi ja niiden käyttö
FI962901L (fi) Uudelleendispergoitava dispersiojauheseos, sen valmistusmenetelmä ja sen käyttö
EE9700145A (et) Tsükloalkaanpüridiinid, nende valmistamismeetod, kasutamine ravimite tootmiseks ja nimetatud ühendeid sisaldavad ravimid
EE04042B1 (et) Suure bioomastatavusega fenofibraatide ravimkoostis ja meetod selle valmistamiseks
FI953898A7 (fi) Glysiiniamidijohdannaisia, menetelmiä niiden valmistamiseksi ja niitä sisältäviä lääkeaineita
EE200000186A (et) Osake, selliste osakeste valmistamismeetod ja kasutamine, farmatseutiline doosivorm ja selle valmistamismeetod, tahke dispersioon ja farmatseutiline pakend
FR2742751B1 (fr) Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2727411B1 (fr) Nouveaux derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent
EE9800302A (et) Arüülglütsiinamiidi derivaadid, nende valmistamismeetod ja kasutamine ning farmatseutiline preparaat
GB9927132D0 (en) Benzimidazole pharmaceutical composition and process of preparation
EE04681B1 (et) 3,6-poolketaalid 9a-asaliidide klassist, nende valmistamismeetod ja farmatseutiline kompositsioon
FR2732968B1 (fr) Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757166B1 (fr) Derives du pyrrole, leur preparation et les compositions pharmaceutiques qui les contiennent
EE04119B1 (et) Külmkuivatamiseks sobiv ravimkoostis ja selle valmistamise meetod
FR2745814B1 (fr) Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
EE04087B1 (et) Antimükootiline kompositsioon, selle kasutamine ja valmistamismeetod ning antimükootiline toode
EE9800075A (et) Kombineeritud ravimpreparaat, selle kasutamine ja meetod selle valmistamiseks

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231